ライフサイエンスコーパス: sialyl

1 , 6'-sialyllactosamine, disialyltetraose, 3'-sialyl-3-fucosyllactose, sialyllacto-N-tetraose-a, sialy

2 nation of both peripheral node addressin and sialyl 6-sulfo Lewis X in high endothelial venules, cons

3 Its epitope overlaps with sialyl 6-sulfo Lewis X, an L-selectin recognition determ

4 ulfated oligosaccharide, which overlaps with sialyl 6-sulfo Lewis X, the L-selectin recognition deter

5 was used to generate the C8-iodide, the key sialyl acceptor (electrophile).

6 ant-rat model; and (v) expression of the LOS sialyl acceptor is altered in cells grown without exogen

7 ; (iv) a nanA mutant hypersialylates its LOS sialyl acceptor, corresponding to an apparent increased

8 with the 5-azido-d-glycero-d-gulo-configured sialyl adamantanylthioglycoside at -78 degrees C are sel

9 rmed that the major sialylated species has a sialyl-alpha-(2-3)-lactosyl extension off the distal hep

10 up strongly reduced the inhibitory effect of sialyl alpha2-->1 Sph on GM3-dependent adhesion, FAK, an

11 Incubation of B16 cells with 0.5-10 microM sialyl alpha2-->1 Sph or 1-5 microM lyso-GM3 reduced GM3

12 ted by clusters of GM3 in GSD, is blocked by sialyl alpha2-->1 Sph or lyso-GM3.

13 Analogues with N-substitution of Sph in sialyl alpha2-->1 Sph, other lyso-phospholipids, and gal

14 .5-10 microM did not show the same effect as sialyl alpha2-->1 Sph.

15 ted from B16 cells was inhibited strongly by sialyl alpha2-->1 Sph.

16 mpound so far found with these properties is sialyl alpha2-->1 sphingosine (Sph).

17 the normally cryptic core Tn (GalNAc), STn (sialyl alpha2-6 GalNAc), and TF (Gal beta1-3 GalNAc) car

18 To clarify the role of milk oligosaccharide sialyl(alpha2,3)lactose (3SL) in intestinal physiology a

19 Sialyl and especially sulfated glycans are difficult to

20 of two independent ancestral genes encoding sialyl- and galactosyltransferase activity.

21 mately 66% of the glycan pool, with alpha2-6-sialyl core 1 being the predominant O-glycan structure i

22 Of greater interest was the creation of a sialyl-di-Lewis(a)-targeting i129G1 mAb via introduction

23 A novel 8-O-picoloylated sialyl donor has been developed, and the performance of

24 -O-oxazolidinone-protected 1-adamantanylthio sialyl donor high alpha-selectivities could be achieved

25 UMP-NeuAc, which was found to be an inactive sialyl donor.

26 These sialyl donors gave high yields and excellent alpha-anome

27 and the performance of various picoloylated sialyl donors in glycosylations with primary glycosyl ac

28 8-O-Picoloyl and 4,9-di-O-picoloyl sialyl donors produced moderate to excellent yields of d

29 ure of the synthetic approach was the use of sialyl donors that were protected with a C-5 trifluoroac

30 ferences in the hydrogen-bonding net between sialyl donors.

31 mplex, and hybrid subtypes such as sulfo and sialyl forms.

32 A series of sialyl fucosyl poly-N-acetylgalactosamine gangliosides w

33 cbeta1,3Galalpha-O-Me] structures containing sialyl, fucosyl, sulfo, methyl, or fluoro substituents b

34 nalyzed the expression of sialyl Lewis X and sialyl-fucosylated core 2 O-glycan (CHO-131 antigen), re

35 effects for hydrolysis of sialyl-lactose and sialyl-galactose were 1.016 +/- 0.011 and 1.015 +/- 0.00

36 beta-dideuterium and primary 13C effects for sialyl-galactose were 1.060 +/- 0.008 and 1.032 +/- 0.00

37 trate, sialyl-lactose, and a slow substrate, sialyl-galactose, in both acid-catalyzed solvolysis and

38 bopentaose (Gb5), fucosyl-Gb5 (Globo H), and sialyl-Gb5 (SSEA4) by using overexpressed glycosyltransf

39 ,3Galbeta1,3GalNAcalpha unit of O-glycans, 3-sialyl globo unit of glycolipids, and sialylated macromo

40 ngliosides sialyl-lactotetraosylceramide and sialyl-globotetraosylceramide, and the sulfated glycosph

41 The resulting 77 sialyl glycans were purified and quantified, characteriz

42 em to generate alpha2-3- and alpha2-6-linked sialyl glycans with 16 modified sialic acids.

43 the preparative synthesis of representative sialyl glycoconjugates has been demonstrated.

44 SSEA-4, a sialyl-glycolipid, has been commonly used as a pluripote

45 opoiesis may be regulated not by the hepatic sialyl glycoproteins, but by the ST6Gal-1 that was relea

46 ifferentially O-protected N-nitroso-N-acetyl sialyl glycosides and of isotopic labeling studies.

47 dative deamination of the N-nitroso-N-acetyl sialyl glycosides leading with overall retention of conf

48 loped on the basis of the equilibration of O-sialyl hydroxylamines by reversible homolytic scission o

49 rus HA with bivalent displays of the natural sialyl-LacNAc ligand.

50 The bivalent scaffolds presented two sialyl-LacNAc ligands in 23-101 A distance.

51 s as ST3[Galbeta1,4GlcNAc] < or = alpha1,3FT[sialyl-LacNAc] < beta1,3GlcNAcT.

52 tterns range from common sialyl Lewis(x) and sialyl lacto-chains to chemically functionalized carbohy

53 erated sialic acid from colominic acid (2-8' sialyl lactose).

54 demonstrated activity on both 2-3' and 2-6' sialyl lactose, while NanH demonstrated activity only on

55 hile NanH demonstrated activity only on 2-3' sialyl lactose.

56 rimary 13C isotope effects for hydrolysis of sialyl-lactose and sialyl-galactose were 1.016 +/- 0.011

57 The beta-dideuterium isotope effect for sialyl-lactose in the acid hydrolysis reaction was 1.113

58 effects were measured for a good substrate, sialyl-lactose, and a slow substrate, sialyl-galactose,

59 These findings identify sialyl-lactotetra as a promising marker of undifferentia

60 ion of hiPSC into hepatocyte-like cells, the sialyl-lactotetra epitope was rapidly down-regulated and

61 A high cell surface expression of sialyl-lactotetra on hESC and human induced pluripotent

62 ochemistry showed distinct cell surface anti-sialyl-lactotetra staining on all seven hESC lines and t

63 id glycosphingolipids, like the gangliosides sialyl-lactotetraosylceramide and sialyl-globotetraosylc

64 ) and sialyl Le(x) or domain antibody 25 and sialyl Le(x) acted synergistically.

65 unoblotting with an antibody specific to the sialyl Le(x) carbohydrate epitope detected expression on

66 Combinations of Le(b) and sialyl Le(x) or domain antibody 25 and sialyl Le(x) acte

67 acetylgalactosamine gangliosides without the sialyl-Le epitope, collectively termed, have been shown

68 Sulfated forms of sialyl-Le(X) containing Gal-6-SO(4) or GlcNAc-6-SO(4) ha

69 ll adhesion assays, anti-Le(x), but not anti-sialyl-Le(x) monoclonal antibodies, inhibited the format

70 FucT-VI catalyzes primarily the synthesis of sialyl-Le(x).

71 two isomeric monofucosyl antigens, VIM2 and sialyl-Le(x).

72 se E-selectin, although they did not express sialyl-Le(X).

73 a mucin, isomeric oligosaccharide sequences, sialyl-Lea- and sialyl-Lex-active, could be resolved by

74 ted by protein-specific O-glycosylation with sialyl Lewis A (sLe(a)).

75 Sialyl Lewis A (sLeA, also known as CA19-9), a tetrasacc

76 The Sialyl Lewis A antigen, or CA 19-9, is the prototype ser

77 e inhibited the binding of sialyl Lewis X or sialyl Lewis A oligosaccharides to E-selectin.

78 , E- and P-selectins, are thought to mediate sialyl Lewis A/X-dependent hematogenous cancer metastasi

79 P-selectin blocking monoclonal antibodies or sialyl Lewis tetrasaccharide inhibits the enhanced adher

80 Moreover, sialyl Lewis x (17) was synthesized via the enzymatic fu

81 osylated glycan receptors, including 6-sulfo-sialyl Lewis x (6-sulfo-sLe(x)).

82 L-selectin binds to the sulfated sialyl Lewis x (6-sulfo-sLex) epitope present on O-glyca

83 pating in the synthesis of core 2-associated sialyl Lewis x (C2-O-sLe(x)), a ligand involved in selec

84 idue with a core 2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)).

85 an adjacent core-2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)).

86 de 1) diminishes the formation of the glycan sialyl Lewis X (Neu5Acalpha2-3Galbeta1-4(Fucalpha1-3) Gl

87 E-selectin glycoprotein ligand(s); distinct sialyl Lewis X (or HECA-452 antigen)-bearing membrane pr

88 ual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3]

89 the canonical E-selectin binding determinant sialyl Lewis X (sLe(X)) and display markedly greater adh

90 A. phagocytophilum binding to sialyl Lewis x (sLe(x)) and other sialylated glycans tha

91 emarkably, an increment of host-cell-surface sialyl Lewis X (sLe(X)) exacerbates the killing by sever

92 A sialyl Lewis X (sLe(x)) mimetic compound, 2-(trimethylsi

93 ligand sulfotransferase (LSST) forms 6-sulfo sialyl Lewis x (sLe(x)) on both core 2 branch and MECA-7

94 Sialyl Lewis X (sLe(X)) on prostate cancer (PCa) cells i

95 Clustered presentation of sialyl Lewis X (sLe(X)) on tumor cell mucins is thought

96 lpha1-3-fucosylated selectin ligands such as sialyl Lewis x (sLe(x)), although monoclonal antibodies

97 ty by ablating N-acetyllactosamine (LacNAc), sialyl Lewis X (sLe(X)), and related lectin ligands on e

98 hesion proteins P- and L-selectin binding to sialyl Lewis X (sLe(X))-containing ligands, and the myos

99 an intragranulocytic bacterium that utilizes sialyl Lewis x (sLe(x))-modified P-selectin glycoprotein

100 osylated to form glycan determinants such as sialyl Lewis x (sLe(x)).

101 Sialyl Lewis X (sLex) mimetics that can function as sele

102 Sialyl Lewis X (sLeX) regulates T cell trafficking from

103 erases that construct the glycan determinant sialyl Lewis x (sLex).

104 tment resulted in dose-dependent ablation of sialyl Lewis X and CHO-131 antigen expression on PSGL-1,

105 eactive with HECA-452, a mAb that recognizes sialyl Lewis X and related structures.

106 ere inhibited, we analyzed the expression of sialyl Lewis X and sialyl-fucosylated core 2 O-glycan (C

107 re colon cancer HT29 cells by using multiple Sialyl Lewis X antibodies (aSlex)-conjugated PAMAM dendr

108 ts, we propose possible pathways for 6-sulfo sialyl Lewis x biosynthesis and suggest that sulfation m

109 Pre-incubation of SSL11 with the glycan Sialyl Lewis X blocked SSL11 function and de-glycosylati

110 and glycosphingolipid structures displaying sialyl Lewis X epitopes as potential E-selectin ligands

111 ranose) action by contrasting the effects on sialyl Lewis X expression displayed by P-selectin glycop

112 It has been established that sialyl Lewis x in core 2 branched O-glycans serves as an

113 tes, although less than CHO cells expressing sialyl Lewis x in core 2 branched O-glycans.

114 nsfected cells carried comparable amounts of sialyl Lewis x in extended core 1 and core 2 branched O-

115 These results indicate that sialyl Lewis x in extended core 1 O-glycans can function

116 In a rolling assay, CHO cells expressing sialyl Lewis x in extended core 1 O-glycans supported a

117 To determine the roles of sialyl Lewis x in extended core 1 O-glycans, Chinese ham

118 critical function of N-glycan-linked 6-sulfo sialyl Lewis X in L-selectin-dependent lymphocyte homing

119 Sulfation of GlcNAc within sialyl Lewis x is a crucial modification for L-selectin

120 ied a class of N-glycans bearing the 6-sulfo sialyl Lewis X L-selectin ligand in high endothelial ven

121 Sialyl Lewis X moieties are critical for ligand activity

122 at adding fucose to human Tregs, forming the Sialyl Lewis X moiety on P-selectin glycoprotein ligand-

123 to recognize both nonsulfated and 6-sulfated sialyl Lewis X on core 2 branched O-glycans, and MECA-79

124 AcT) enabled the construction of the 6-sulfo sialyl Lewis x on extended core1 O-glycans, recapitulati

125 phocytes and the carbohydrate ligand 6-sulfo sialyl Lewis X on high endothelial venules.

126 sulfated carbohydrate structures (6-sulfated sialyl Lewis x or 6-sulfo-sLex) as a recognition determi

127 g the same sequence inhibited the binding of sialyl Lewis X or sialyl Lewis A oligosaccharides to E-s

128 This binding requires the sialyl Lewis x sugar moiety to be placed on both O- and

129 n of HL-60 and B16 melanoma cells expressing sialyl Lewis X to E-selectin was also inhibited by the p

130 ied NK-92MI cells with the E-selectin ligand sialyl Lewis X to promote trafficking to bone marrow.

131 utant mice, whereas the amount of unsulfated sialyl Lewis X was much greater.

132 kingly, bonds between L-selectin and 6-sulfo-sialyl Lewis X were impervious to ramp rate changes.

133 for a sulfated-glycan binding site (6-sulfo-sialyl Lewis x) on peripheral node addressin.

134 and fucosylated alpha2-3 glycans (including sialyl Lewis x), both of which may be important receptor

135 rate structural analysis showed that 6-sulfo sialyl Lewis X, a dominant ligand for L-selectin, was al

136 This epitope overlaps with 6-sulfo sialyl Lewis x, a recognition determinant for L-selectin

137 m the neutrophil surface during rolling on a sialyl Lewis x-coated planar surface at physiological sh

138 -selectin on neutrophils during rolling on a sialyl Lewis x-coated surface that involves mechanical f

139 We tested this hypothesis using sialyl Lewis X-dependent B16 melanoma lung targeting and

140 n the lung vasculature plays a major role in sialyl Lewis X-dependent cancer cells targeting to the l

141 n E/P-selectin doubly deficient mutant mice, sialyl Lewis X-expressing B16 melanoma cells colonized t

142 carbohydrate-dependent lung colonization of sialyl Lewis X-expressing B16-FTIII-M cells in E/P-selec

143 ctable sulfation of GlcNAc in the context of sialyl Lewis x.

144 that comprise structural motifs derived from sialyl Lewis x.

145 lanoma and human lung tumor cells expressing sialyl Lewis X.

146 humans through the generation of functional sialyl Lewis X.

147 (MB) functionalized with the selectin ligand sialyl Lewis(a) individually (MBsLea) or dually with sLe

148 A expression) and new biomarkers (levels of sialyl Lewis(a), Lewis(x), and Aspergillus oryzae lectin

149 l bubbles (MB(CTL)) bore surface Lewis(x) or sialyl Lewis(c).

150 Sialyl Lewis(x) (sLe(x)) and Lewis(x) (Le(x)) are known

151 Monomeric sialyl Lewis(X) (sLe(x)) and sLe(x)-like oligosaccharide

152 have reported that microspheres coated with sialyl Lewis(x) (sLe(x)) interact specifically and roll

153 -terminus of PSGL-1 through recognition of a sialyl Lewis(x) (SLe(x)) moiety linked to a properly pos

154 Binding of the P-, L-, and E-selectins to sialyl Lewis(x) (sLe(x)) retards circulating leukocytes,

155 nanometer-scale polymer construct containing sialyl Lewis(x) (sLe(x)) that is found on the surface of

156 f L-selectin and the minimal selectin ligand sialyl Lewis(x) (sLe(x)) to interact with postcapillary

157 res functionalized with the selectin ligand, sialyl Lewis(X) (sLe(X)), and an antibody against ICAM-1

158 ds are glycosylated with the tetrasaccharide sialyl Lewis(x) (sLe(x)), which contributes to bond affi

159 However, the only millimolar affinity of sialyl Lewis(x) (sLe(x)), which is the common tetrasacch

160 ted in a cell-free system; it was shown that sialyl Lewis(x) (sLe(x))-coated microspheres roll over E

161 omplex with its prime glycan target 6'-sulfo sialyl Lewis(x) A canonical motif for sialic acid recogn

162 Reported herein is the synthesis of sialyl Lewis(X) analogues bearing a trans-bicyclo[4.4.0]

163 nhibitors of selectin binding to immobilized sialyl Lewis(X) and of cell adhesion to immobilized sele

164 introduced glyco-patterns range from common sialyl Lewis(x) and sialyl lacto-chains to chemically fu

165 ide but does not bind to GM1, GD1a, GT1b, or sialyl Lewis(X) antigens.

166 egulation of endothelial selectins that bind sialyl Lewis(x) ligands and activation of beta(2)-integr

167 Furthermore, saliva/sialyl Lewis(X) mediated signaling enhanced intracellula

168 d SIGNR7 binds preferentially to the 6-sulfo-sialyl Lewis(x) oligosaccharide, whereas SIGNR2 binds al

169 volving the binding of P- and L-selectins to sialyl Lewis(X) oligosaccharide-containing ligands.

170 Here we show that binding of E-selectin to sialyl Lewis(x) on L-selectin and PSGL-1 drives their co

171 intracellular signals elicited by binding of sialyl Lewis(X) present on salival mucins to l-selectin

172 ger than that for integrin binding to RGD or sialyl Lewis(x) to E-selectin.

173 The selectin ligand sialyl Lewis(x) was conjugated to the microbubble surfac

174 relevant branched oligosaccharides, such as sialyl Lewis(x), as well as sulfated glycosaminoglycan-l

175 -long glass fibers, and the selectin ligand, sialyl Lewis(x), was coupled to latex microspheres.

176 nd CD11b are all required for PMN binding to sialyl Lewis(x)-bearing LS174T cells at high shear (800

177 In contrast, sialyl Lewis(x)-low HCT-8 cells fail to aggregate with P

178 test the hypothesis that plasma C1INH bears sialyl Lewis(x)-related moieties and therefore binds to

179 demonstrated that plasma C1INH does express sialyl Lewis(x)-related moieties on its N-glycan as dete

180 -detectable glyconanoparticles conjugated to sialyl Lewis(X).

181 provide functional oligosaccharides such as sialyl Lewis(X).

182 uring selectin recognition, since sLe(X) and sialyl Lewis-a (sLe(a)) were approximately 5-7-fold poor

183 in E-selectin (CD62E) to its cognate ligand, sialyl Lewis-X (sLe (X) ), displayed on circulating cell

184 binding of simple oligosaccharides based on sialyl Lewis-X (sLe(X)) and complex molecules with the c

185 amine structure (Galbeta1,4GlcNAc) to create sialyl Lewis-X (sLe(X)) and related sialofucosylated gly

186 nalysis demonstrate the presence of both the sialyl Lewis-X (sLe(X)) and the di-sialylated T-antigen

187 rks that participate in the formation of the sialyl Lewis-X (sLe(X)) epitope on O-glycans linked to a

188 r conventional Hbonds in the pentasaccharide sialyl Lewis-X (sLe(X)-5) between 5 and 37 degrees C in

189 inhibitor to reduce O-linked glycosylation, sialyl Lewis-X formation, and leukocyte adhesion via the

190 Resulting reduction in the sialyl Lewis-X-bearing epitopes on this ligand may reduc

191 presses vertebrate motifs such as sulfo- and sialyl-Lewis A epitopes but displays a high degree of an

192 rotein production and increased adherence to sialyl-Lewis antigens and mouse gastric tissue.

193 The sabA gene encodes an adhesin that binds sialyl-Lewis antigens on inflamed gastric tissue.

194 Core 2 O-glycans terminated with sialyl-Lewis x (sLe(X)) are functionally important oligo

195 Sialyl-Lewis X (sLe(X)) is a tetrasaccharide that serves

196 -sialylated- and alpha1,3-fucosylated-moiety sialyl-Lewis x (sLe(x)), which modifies the PSGL-1 N ter

197 deep within corpus glands in vivo only when sialyl-Lewis X expanded during SPEM.

198 ysis confirmed the expression of Lewis X and sialyl-Lewis X in the intracellular granules and on the

199 rough interaction of its adhesin, SabA, with sialyl-Lewis X, which expanded in SPEM.

200 d in mice, in large part by interacting with sialyl-Lewis X.

201 ro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on

202 pport the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemina

203 sferase 5 in mice, reconstituting the glycan sialyl-Lewis(a), also known as carbohydrate antigen 19-9

204 (AFM) with cantilevers biofunctionalized by sialyl-Lewis(x) (sLe(x)) were employed to investigate Ab

205 s and displays copies of the tetrasaccharide sialyl-Lewis(x) (sLe(X)), as well as a cluster of three

206 -selectin glycoprotein ligand-1 [PSGL-1] and Sialyl-Lewis(x) [SLeX]) to rapidly target inflamed tissu

207 detect binding of the SabA adhesin domain to sialyl-Lewis(X) and Lewis(X) but not to Lewis(A), Lewis(

208 es the binding of the SabA adhesin domain to sialyl-Lewis(X) and Lewis(X).

209 eu5Acalpha2-3Galbeta1-4GlcNAc, including the sialyl-Lewis(x) motif and structures containing 6-sulfog

210 ass spectrometric analyses revealed that the sialyl-Lewis(x) sequence [NeuAcalpha2-3Galbeta1-4(Fucalp

211 Thus, the sialyl-Lewis(x) sequence represents the major carbohydra

212 inhibited by glycoconjugates terminated with sialyl-Lewis(x) sequences or by antibodies directed agai

213 We have shown that C1INH expresses the sialyl-Lewis(x) tetrasaccharide on its N-linked glycan,

214 uraminic acid, 5-N-glycolyl neuraminic acid, sialyl-Lewis(X), alpha2,3-sialyl-N-acetyl-lactosamine an

215 bind tightly to sugar moieties Lewis(B) and sialyl-Lewis(X), respectively, on the surface of epithel

216 ell binding is because of markedly decreased sialyl-Lewis(x/a) (sLe(x/a)) carbohydrate ligand-binding

217 Results demonstrate that 1) the sLe(X) (sialyl-Lewis-X) epitope is expressed in P-selectin glyco

218 oll" (via interactions between selectins and sialyl-Lewis-x), and then firmly adhere to the vascular

219 features with the soluble E-selectin ligand, sialyl Lewisx (sialyl Lex).

220 The selectins bind weakly to sialyl Lewisx (SLe(X))-like glycans, but with high-affin

221 ed that Ply has the highest affinity for the sialyl LewisX (sLeX) structure, with a K(d) of 1.88 x 10

222 oproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endoth

223 terminus and by the crucial tetrasaccharide sialyl LewisX produces dramatic changes in the failure k

224 ly related to the soluble E-selectin ligand, sialyl Lewisx, and is selectively expressed in skin, lym

225 he soluble E-selectin ligand, sialyl Lewisx (sialyl Lex).

226 c oligosaccharide sequences, sialyl-Lea- and sialyl-Lex-active, could be resolved by HPLC as fluoresc

227 binding affinity to SNA, while alteration in sialyl linkage and terminal sialic acid structure compro

228 eptides that are mass tagged to identify the sialyl linkage, thus facilitating the analysis of these

229 Structures of the sialyl-linkage isomers were assigned indirectly through

230 erum from CRC patients, where a level of six sialyl-linkage isomers were found to be altered signific

231 Their sialyl-linkage isomers, mostly alpha-2,3- and alpha-2,6-

232 and non-natural sialic acid forms, different sialyl linkages and different glycans that link to the s

233 carbohydrate motifs, allowing distinction of sialyl linkages and investigation pertaining to the effe

234 Differentiation between the sialyl linkages is often critical to understanding biolo

235 seudotype with a negatively charged sulfated sialyl lipid (NMSO3) displayed a approximately 4-fold-hi

236 and replication, that is, NMSO3, a sulfated sialyl lipid compound, and ribavirin, respectively.

237 in outer membrane presentation of unnatural sialyl-LOS.

238 t express a CD44 glycoform bearing alpha-2,3-sialyl modifications.

239 c residues and is equidistant from the large sialyl motif in both polysialyltransferases.

240 l neuraminic acid, sialyl-Lewis(X), alpha2,3-sialyl-N-acetyl-lactosamine and alpha2,6-sialyl-N-acetyl

241 2,3-sialyl-N-acetyl-lactosamine and alpha2,6-sialyl-N-acetyl-lactosamine at 2.7-3.0 angstrom resoluti

242 ted in the loss of glycoforms terminating in sialyl-N-acetylhexosamine and the appearance of higher m

243 ncludes N-terminal synthetase and C-terminal sialyl O-esterase domains.

244 Mono-sialyl O-glycans represented approximately 66% of the gl

245 g that relied on multivalent ligation of BCR sialyl-oligosaccharide.

246 ialic acids modification for the analysis of sialyl oligosaccharides and glycopeptides.

247 libration of 1 and mass spectral analysis of sialyl phosphates suggest that the 4O,5N-oxazolidinone a

248 oited for the enzymatic synthesis of diverse sialyl products.

249 dicals) poor kinetic selectivity of anomeric sialyl radicals is discussed in terms of the planar pi-t

250 teins that reduced virus binding to alpha2,3-sialyl receptor and NA activity.

251 ants bind a broader range of alpha2-3-linked sialyl receptor sequences of a type expressed on ciliate

252 nding affinity for synthetic alpha2,6-linked sialyl receptor.

253 tor-binding domain determines the species of sialyl receptors recognized by influenza viruses.

254 igenic phenotype also impacted HA binding to sialyl receptors that are usually present in the human r

255 together with decreasing binding to alpha2,6 sialyl receptors.

256 rases (polySTs) responsible for polymerizing sialyl residues from donor CMP-sialic acid are not homol

257 We previously reported that removal of sialyl residues primed PBMCs to respond to bacterial LPS

258 acid units on their surfaces, mimicking the sialyl-rich mucin layer coating epithelial cells and the

259 electively binds MUC1 that carries the Tn or sialyl (S)Tn glycan.

260 ta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), stru

261 The occurrence of T- and sialyl T-antigen varied in bovine and ovine reproductive

262 n of mucin origin, with terminal fucose, the sialyl T-antigen, and N-linked oligosaccharides identifi

263 significant amounts of elaborated O-glycans (sialyl-T and disialyl-T) which were inhibited upon treat

264 mine [NeuAcalpha(2-3)Galbeta(1-4)GlcNAc] and sialyl-T antigen [NeuAcalpha(2-3)Galbeta(1-3)GalNAc], wh

265 3)GalNAc], whereas the BR of GspB only bound sialyl-T antigen.

266 of the Golgi, resulting in the formation of sialyl-T antigen.

267 r marker MUC1 carrying one or more Tn, T, or sialyl-T antigens.

268 Conversely, specific inhibition of MAG or sialyl-T MUC1 partially blocked adhesion.

269 DC with sialyl-Thomsen-Friedenreich antigen (Sialyl-T) suggests that BoNT/DC recognizes only the sial

270 lls, bearing MUC1 that predominantly carries sialyl-TF, only demonstrated an adhesive response to gal

271 Two N-acetyl 4O,5N-oxazolidinone-protected sialyl thioglycosides epimeric at the 7-position have be

272 Sialyl Thomsen-nouveau (STn) is a tumor-associated carbo

273 The co-crystal structure of BoNT/DC with sialyl-Thomsen-Friedenreich antigen (Sialyl-T) suggests

274 saccharide motif alone, corresponding to the sialyl-Thomsen-Friedenreich antigen, that represents the

275 mor-associated carbohydrate antigens, Tn and sialyl Tn (STn), result from somatic mutations in the ge

276 d mucin in PanINs is an early event, whereas sialyl Tn expression is a late event in the recently def

277 and mucin-associated tumor antigens (Nd2 and sialyl Tn) in these precursor lesions.

278 on of mucin-associated carbohydrate antigen, sialyl Tn, was markedly increased only in PanlN-3 and in

279 ing protein 1) showed significant binding to sialyl-Tn (Neu5Acalpha2-6-GalNAc), a tumor marker associ

280 ed O-glycans, Tn (GalNAcalpha1-Ser/Thr), and Sialyl-Tn (Siaalpha2-6GalNAcalpha1-Ser/Thr, STn) on thei

281 ated sialylated O-glycans, the disaccharide, sialyl-Tn (sialic acid alpha2,6GalNAc), is expressed by

282 ied with immunoperoxidase staining of CD11b, sialyl-Tn (sTn) antigen (Ag), and gamma immunoglobulin (

283 and discrimination of the cancer-associated sialyl-Tn (STn) antigen was developed by using Sambucus

284 GalNAc-Ser/Thr) and its sialylated form, the sialyl-Tn antigen.

285 Finally, the presentation of the sialyl-Tn epitope and/or more extended structures that i

286 ns of certain mucins and weak binding to the sialyl-Tn epitope.

287 rt) H259T mutant failed to interact with the sialyl-Tn epitope.

288 A-encoding ST6GalNAc-I and the expression of sialyl-Tn is evident, demonstrating that the expression

289 large scale production of MUC1 carrying 83% sialyl-Tn O-glycans.

290 vident, demonstrating that the expression of sialyl-Tn results from switching on expression of hST6Ga

291 Galbeta1-4GlcNAc and that Siaalpha2-6GalNAc (sialyl-Tn) is rare in mice.

292 u5Gc incorporation into the carcinoma marker Sialyl-Tn, and is the first example of such a novel mech

293 lNAc-II) always results in the expression of sialyl-Tn.

294 S were characterized for their activity in a sialyl transfer assay.

295 f genes encoding proteins with homology to a sialyl transferase (cstII) and a putative N-acetylmannos

296 not exactly co-locate with the Golgi marker sialyl transferase (ST)-mRFP, nor with the t-SNAREs Memb

297 e fused the signal anchor sequences of a rat sialyl transferase and a human galactosyl transferase al

298 lysosomal-associated membrane protein 1, and sialyl transferase are not recruited.

299 e natural GlcNAc, followed by sialylation by sialyl transferases gave 12 differently fucosylated and

300 ly charged version binds the important alpha-sialyl unit with K1 approximately 1300 m(-1) .